Wassil Nowicky
Nowicky Pharma-Ukrainian Anti-Cancer Institute, Austria
Title: Anti-cancer preparation NSC-631570 (Ukrain) and its effi cacy in the treatment of breast cancer
Biography
Biography: Wassil Nowicky
Abstract
In a controlled clinical study conducted at the University Grodno (Grodno, Belarus), aft er the therapy with NSC-631570 the
hardening of the tumor, a slight increase in the tumor size (5-10%) and proliferation of connective tissues were observed. Th e
tumours appeared harder and slightly enlarged aft er NSC-631570 therapy, and were easier to detect by ultrasound or radiological
examination. Metastatic lymph nodes were also hardened and sclerotic (fi brous). Tumours and metastatic lymph nodes were
clearly demarcated from healthy tissue and therefore easier to remove. Complications such as prolonged lymphorrhoea (leakage
of lymph onto the skin surface), skin necrosis (death of skin tissue), suppuration of the wound, and pneumonia, all occurred
in patients from the two NSC-631570 groups at only half the rate that they appeared in patients from the control group. Based
on the results of this study the scientists from Grodno recommended the use of NSC-631570, at the higher dosage, in all breast
cancer operations. Other parameters were also evaluated, e.g. hormones (T3, T4, cortisol, progesterone, estradiol, prolactin),
immune values (lymphocytes, immune globulins, complement, phagocytic activity, morphologic and cytochemical changes),
amino acids and their derivates in plasma and in the tumor tissue. Th e eff ect of NSC-631570 on the various parameters in
breast cancer patients has been studied. Best results were achieved with higher dosage of NSC-631570. Almost every patient
noted the improvement of the general well-being, sleep and appetite. During the surgery, the tumors as well as involved lymph
nodes were presented sclerotic and well demarcated from the surrounding tissue. Th is alleviated the surgical removal of the
tumor considerably. In the tumor tissue, increased concentration of the amino acid proline was revealed indicating augmented
production of connective tissue that demarcates the tumor from surrounding tissue. NSC-631570 improved also the amino
acid balance of patients. NSC 631570 is the very fi rst proton anticancer preparation and due to this aft er administration it
accumulates in tumors very fast that can be seen under the UV-light thanks to its the autofl uorescence. Besides this preparation
it can regenerate the immune system and works as an immunomodulating agent. Th e selective eff ect of the NSC 631570 has
been confi rmed by 120 universities and research centers in the world. Until now this preparation has been tested on over 100
cancer cell lines and on 12 normal cell lines. Th e researchers who conducted studies with the anticancer preparation NSC-
631570 concluded that the anticancer drug NSC-631570 exerts its cytotoxic eff ects on both mouse and human breast cancer
cell lines in a dose and time dependent manner. Weeks following NSC-631570 treatment, cells maintained a reduced capacity
to proliferate.